Zhejiang East Asia Pharmaceutical Co. Ltd. (605177.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000077G5

Price
20.02 CNY
Market cap
2.30 bn CNY
P/E (2025)
–
P/S (2025)
2.44
Dividend yield
0.00 %
Net margin
-8.76 %
Return on equity (ROE)
-4.56 %
Return on assets (ROA)
-2.47 %

Zhejiang East Asia Pharmaceutical Co. Ltd. financials

Fiscal year20242025
Revenue1.20 bn CNY940.19 m CNY
Gross profit194.21 m CNY222.07 m CNY
Operating income-101.73 m CNY-30.53 m CNY
EBIT-115.36 m CNY-71.23 m CNY
Net income-100.66 m CNY-82.39 m CNY
Diluted EPS – continuing operations-0.90 CNY-0.72 CNY

Full history since 2016, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Zhejiang East Asia Pharmaceutical Co. Ltd.

Zhejiang East Asia Pharmaceutical Co., Ltd., together with its subsidiaries, produces and sells pharmaceutical chemicals, tablets, granules, intermediates, and capsules in China and internationally. It offers quinolones synthetic antibacterial agents, antifungal products, gastrointestinal medications, semi-synthetic cephalosporin antibiotics, carbapenem antibiotics, antiviral agents, central nervous system medications, respiratory drugs, antiallergic agents, antineoplastic agents and tumor adjuvant drugs, and other products. The company's products are used in cardiovascular, anti-aging, dementia, digestive system, diabetic neuropathy, anti-pathogenic microorganisms, infection, and central nervous system fields. It exports its products. The company was founded in 1998 and is headquartered in Taizhou, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.